Pfizer stock stands 3.97 percent above USD 28.72 consensus target

Published on 10/26/2026 at 16:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Erste cut its estimate to USD 2.96 on October 21, 2026. Pfizer stock costs EUR 26.68 on October 26, 2026, 0.74 percent below the Xetra close.

Analyst target and earnings date

MarketBeat cited a USD 28.72 consensus target from 21 analysts on October 26, 2026.
Erste Group Bank cut its fiscal-year 2026 earnings estimate to USD 2.96 from USD 2.97 on October 21, 2026.
Pfizer stock costs EUR 26.68 at Lang & Schwarz on October 26, 2026 at 4:40 p.m. CEST, minus 0.74 percent versus the Xetra close of October 23, 2026.
Pfizer is scheduled to report third-quarter 2026 results on November 3, 2026.

Pfizer Inc., US7170811035, Illustration mit AI erstellt.

Pfizer Inc. (ISIN US7170811035) stands 3.97 percent above the USD 28.72 consensus target compiled from 21 analyst ratings, according to MarketBeat on October 26, 2026. Erste Group Bank also cut its fiscal-year 2026 earnings estimate to USD 2.96 from USD 2.97 on October 21, 2026, the same report said. Pfizer was trading at EUR 26.68 at Lang & Schwarz on October 26, 2026 at 4:40 p.m. CEST, minus 0.74 percent versus the Xetra close of October 23, 2026 at EUR 26.88.

Estimate cut leaves target above price

The analyst update puts the current US valuation slightly above the consensus target. Pfizer's NYSE price was USD 29.86 on October 26, 2026 at 11:49 a.m. ET, which is 3.97 percent above the USD 28.72 target. Erste's revised USD 2.96 estimate remains above the USD 2.94 consensus cited by MarketBeat.

What does the price position show?

The NYSE price sits 1.91 percent below Pfizer's 52-week high of USD 30.44 and 26.78 percent above its 52-week low of USD 23.62, as of October 26, 2026. Pfizer's stock was up 20.60 percent in 2026 through October 23, 2026. Its market capitalization was USD 170.2 billion, with a price-to-earnings ratio of 39.42 and a dividend yield of 6.00 percent as of October 26, 2026.

November 3 brings the next report

Pfizer is scheduled to announce its third-quarter 2026 results on November 3, 2026, according to Yahoo Finance. The calendar lists a before-market announcement and a consensus earnings-per-share estimate of USD 0.73. The date gives the next clear checkpoint for comparing the current target gap with Pfizer's reported operating performance.

Comparison with peers

Pfizer Inc.: minus 0.58 percent, price-to-earnings ratio 39.42, market capitalization USD 170.2 billion.

Bristol-Myers Squibb Company (NYSE, USD): minus 0.40 percent, price-to-earnings ratio 13.49, market capitalization USD 125.1 billion.

Merck & Co., Inc. (NYSE, USD): minus 2.36 percent, price-to-earnings ratio 113.81, market capitalization USD 349.9 billion.

Stock stays below the yearly high

Pfizer's euro quotation is below its Xetra close, while the US-listed stock remains close to its 52-week high in dollar terms. The next earnings release on November 3 will provide the next dated test for the estimate and valuation figures.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.